Muscle disease in scleroderma is common and is associated with poor outcomes such as disability and sudden cardiac death. We have developed a sub-cohort of weak scleroderma patients and are beginning to study the mechanisms driving muscle disease and also interventions to halt or improve strength in this special group of patients.
My secondary research interest is in novel therapeutics in refractory dermatomyositis. In particular, I am interested in JAK inhibitor therapy in refractory dermatomyositis and have led a pilot study of tofacitinib in refractory dermatomyositis.
Clinical Trial Keywords
Dr. Paik is a principal investigator in the study of tofacitinib in refractory dermatomyositis. She is also a co-investigator in other trials in scleroderma and myositis.
Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, Boin F, Hummers LK, Mammen AL. The spectrum of muscle histopathologic findings in 42 weak scleroderma patients. Arthritis Care Res (Hoboken). 2015 May 18. Doi:10.1002/acr.22620
Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, Gutierrez-Alamillo L, Perin J, Florea L, Antonescu C, Leung SG, Purwin G, Koenig A, Christopher-Stine L. Study of tofacitinib in refractory dermatomyositis (STIR): An open label pilot study of 10 patients. Arthritis Rheumatology 2020 Dec 1. doi:10.1002/art.41602 online ahead of print
Baig SS and Paik JJ. Inflammatory muscle disease- an update. Best Pract Res Clin Rheumatol. 2020 Feb; 34(1):101484
Paik JJ. Muscle disease in scleroderma. Curr Opin Rheumatol. 2018 Nove; 30(6):576-580
Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL. Association of fibrosing myopathy in systemic sclerosis and higher mortality. Arthritis Care Res (Hoboken) 2017 Nov: 69 (11): 1764-1770